Study to Investigate the Effect of GSK1014802 on Ambulatory Blood Pressure

Inclusion Criteria: * Male or female between 18 and 65 years of age inclusive. * Healthy as determined by a responsible and experienced physician, based on a medical evaluation including medical history, physical examination, laboratory tests, liver function and cardiac monitoring. * A female subject is eligible to participate if she is of: Non-childbearing potential Child-bearing potential and agrees to use a contraception method. * Male subjects must agree to use a contraception methods * Body weight ≥ 50 kg and BMI within the range 19 - 40.0 kg/m2 (inclusive). * Arm circumference ≥ 24 and ≤ 42 cm at mid level. * Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form. Exclusion Criteria: * A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody result within 3 months of screening * Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones). * A positive pre-study drug screen. * Alcohol levels above the legal limit for driving at screening and the detection of any alcohol within 24 h prior to the start of dosing in Treatment Periods 1 and 2. * A positive test for HIV antibody. * History of regular excessive alcohol consumption within 6 months of the study * The subject has participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer). * Exposure to more than four new chemical entities within 12 months prior to the first dosing day. * Use of prescription or non-prescription drugs, including any antihypertensive agent including diuretics, vitamins, herbal and dietary supplements * History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy * Where participation in the study would result in donation of blood or blood products in excess of 500 mL within a 90 day period. * Pregnant females as determined by positive serum or urine hCG test at screening or prior to dosing. * Lactating females. * Unwillingness or inability to follow the procedures outlined in the protocol. * Subject is mentally or legally incapacitated. * Subjects who work at night or whose work schedule includes rotating night time (10:00 PM to 6:00 AM) work. * Urinary cotinine levels indicative of smoking or history or regular use of tobacco- or nicotine-containing products within 6 months prior to screening. * Average daily caffeine intake equivalent to \> 4 cups of coffee or \> 6 cups of tea. * Consumption of red wine, seville oranges, grapefruit or grapefruit juice and/or pummelos, exotic citrus fruits, grapefruit hybrids or fruit juices from 7 days prior to the first dose of study medication. * Consumption of aged cheeses and meats, soy sauce and other tyramine rich sources within 1 day prior to the baseline assessments. * Current or past history of symptomatic orthostatic hypotension or history of unexplained vasovagal episode(s). * History of known or suspected seizures, including infantile febrile, unexplained significant and recent loss of consciousness or history of significant head trauma with loss of consciousness or a family history (first degree relative) of epilepsy or seizures (fits). * Any history of suicidal behaviour or suicidal ideation of type 4 or 5 on the C-SSRS within 3 months of the screening visit. * History or currently diagnosed sleep apnea.